source
- Amylyx's avexitide halves hypoglycemia episodes in phase 3 trial for post‑bariatric patientsAmylyx Pharmaceuticals reported that its GLP‑1 receptor antagonist avexitide significantly reduced dangerous blood‑sugar drops in a phase 3 study. The double‑blind Lucidity trial enrolled 78 indiv…
- IRS probes UnitedHealth tax filings and private-equity deals for doctor groups slow downUnitedHealth disclosed that the IRS has opened an investigation into its tax filings for 2017-2020, seeking to increase the company’s taxable income and potentially raise its tax bill for those yea…